Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, announced today that the U.S. Food and Drug Administration ...
Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth ...
LOS ANGELES--(BUSINESS WIRE)--The DJS Law Group reminds investors of a class action lawsuit against Replimune Group, Inc. (“Replimune” or “the Company”) (NASDAQ: REPL) violations of §§10(b) and 20(a) ...
Replimune (REPL) stock dips as the FDA plans an advisory committee meeting after accepting the company's marketing ...
Replimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more ...
Detailed price information for Replimune Group Inc (REPL-Q) from The Globe and Mail including charting and trades.
Well before market open, Replimune announced that the U.S. Food and Drug Administration (FDA) accepted the resubmission of a crucial Biologics License Application (BLA). This was made for its RP1, an ...
FDA reverses course therapies, allowing Replimune's melanoma drug and uniQure's Huntington's gene therapy to advance toward approval.
Detailed price information for Replimune Group Inc (REPL-Q) from The Globe and Mail including charting and trades.
WOBURN, Mass. & WILMINGTON, Del.--(BUSINESS WIRE)--Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results